Progesterone therapy for malignant peritoneal cytology surgical stage I endometrial adenocarcinoma.
Twenty-five patients with surgical stage I endometrial adenocarcinoma and malignant peritoneal cytologic washings were treated with progesterone therapy. Twenty-two patients have undergone a second-look laparoscopy and repeat cytologic washings, one of whom also underwent a third-look laparoscopy. Two patients refused second-look laparoscopy, and in a third patient, a laparoscopy was medically contraindicated; the three patients have no evidence of disease at 15, 46, and 64 months, respectively, and are off therapy. Of the 22 patients who underwent second-look laparoscopy, 21 (95%) had no evidence of recurrent endometrial carcinoma and repeat peritoneal results of cytology were negative for malignant cells; one patient (5%) had persistent malignant peritoneal cytology at second-look laparoscopy but had no evidence of disease at third-look laparoscopy after an additional year of progesterone therapy. All 25 patients (100%) are off progesterone therapy and remain clinically free of disease from 12 to 64 months after discontinuation of therapy.
Piver
M S
MS
Department of Gynecologic Oncology, Roswell Park Memorial Institute, Buffalo, NY 14263.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D010535:Laparoscopy; D010529:Peritoneal Cavity / Q000473:pathology*; D011374:Progesterone / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D011374:Progesterone